Amarin Pharmaceuticals Ireland Limited

Albireo Ab

Amarin Pharma, Inc.

Alexion Pharmaceuticals, Inc.

Paresh Soni

Rene Braeckman

Pierre Wicker

Ian Osterloh

Mehar Manku

Joseph S Zakrzewski

Per-Göran Gillberg

Anthony Quinn

Jan Mattsson

Jonathan Rowe

Pat Horn

Barbara Burton

William Stirtan

Rene Breackman

Zachary Goodman

Andrew Rankin

Mark Friedman

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and/or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Methods of reducing the risk of cardiovascular events in a subject

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Compositions and methods for lowering triglycerides

In various embodiments, the present disclosure provides methods reducing the risk of heart failure in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Methods of reducing the risk of heart failure

In various embodiments, the present invention provides pharmaceutical compositions and methods for treating cardiovascular-related disease.

Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Methods of treating mixed dyslipidemia

Growing community of inventors

Mystic, CT, United States of America

Paresh Soni